A study of the drug zotiraciclib for gliomas with IDH1 or IDH2 gene changes
Original title: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, so we do not know yet if it helps.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a capsule called zotiraciclib in people whose brain tumor came back.
Who this trial is for. This trial is for people 15 years and older whose diffuse glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary came back. It tests a capsule, zotiraciclib, for tumors with IDH1 or IDH2 gene changes.
Where it stands. This trial has not reported results. It is looking at whether zotiraciclib helps people with these tumors. Brain MRI scans are repeated every 8 weeks. Blood tests and heart tests are done too. The answer is not in yet.
What this means, and what it doesn't
What it could mean: People take the capsule at home and visit the clinic about once a month. If this sounds like your situation, you can ask your care team about it. They can help you learn whether a study like this fits you.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Being in a study is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.